MIMS bulletin launched on World Diabetes Day

MIMS has launched a new email bulletin offering a regular round up of essential prescribing news and resources by disease area. Each topical issue of MIMS Spotlight highlights key drug-related developments in a rapidly evolving therapeutic setting.

To coincide with World Diabetes Day on 14 November, the first issue of MIMS Spotlight focussed on diabetes.

In recent months, NICE has updated its guidance on the management of type II diabetes, new hypoglycaemic agents including Onglyza (saxagliptin) have been launched, and experimental treatments such as dapagliflozin have shown promise in late-stage clinical trials.

By drawing together developments like these alongside a selection of quick-reference MIMS resources, MIMS Spotlight helps you:

  • choose the right treatments
  • follow national guidelines
  • support and advise your patients
  • keep abreast of emerging medicines.

The new bulletin is designed to complement the MIMS Product Update, which already provides MIMS users with a monthly email summary of new drugs and licence changes.

Topics to be covered in future editions of MIMS Spotlight include contraception, arthritis and asthma/COPD.


To sign up for MIMS Spotlight or MIMS Product Update, go to www.mims.co.uk/Bulletins/

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

FemSeven Conti back in stock

FemSeven Conti back in stock

FemSeven Conti (estradiol/levonorgestrel) HRT patches...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Trial of interferon beta in COVID-19 patients begins in UK

Trial of interferon beta in COVID-19 patients begins in UK

A global phase III clinical trial to evaluate an inhaled...